Fertility and Sterility
Volume 88, Issue 4 , Pages 779-780 , October 2007

Limiting access to letrozole—is it justified?

  • Togas Tulandi, M.D., M.H.C.M.

      Affiliations

    • Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada
    • Corresponding Author InformationReprint requests: Togas Tulandi, M.D., M.H.C.M., Department of Obstetrics and Gynecology, McGill University, Women's Pavilion, 687 Pine Avenue West, Montreal, H3A 1A1, Quebec, Canada (FAX: 514-843-1448).
    • ,
  • Alan H. DeCherney, M.D.

      Affiliations

    • Reproductive Biology and Medicine Branch, National Institute of Health and Development, Bethesda, Maryland

Received 15 November 2006 ,Revised 22 January 2007 ,Accepted 22 January 2007.

References 

  1. Biljan MM, Hemmings R, Brassard N. The outcome of 150 babies following the treatment with letrozole or letrozole and gonadotropins. [abstract] Fertil Steril. 2005;84(Supp 1):O-231. Abstract 1033
  2. Holzer H, Casper R, Tulandi T. A new era of ovulation induction. Fertil Steril. 2006;85:277–284
  3. Fontana PG, Leclerc JM. Contraindication of Femara® (letrozole) in premenopausal women. Available at: http://www.ca.novartis.com/downloads/en/letters/femara_hcp_e_17_11_05.pdf
  4. Shepard TH. Catalog of teratogenic agents. 10th ed.. Baltimore: Johns Hopkins University Press; 2001;
  5. Tulandi T, Martin J, Al-Fadhli R, Kabli N, Forman R, Hitkari J, et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril. 2006;85:1761–1765
  6. Mitwally MF, Biljan MM, Casper RF. Pregnancy outcome after the use of an aromatase inhibitor for ovarian stimulation. Am J Obstet Gynecol. 2005;192:381–386

PII: S0015-0282(07)00275-0

doi: 10.1016/j.fertnstert.2007.01.115

Fertility and Sterility
Volume 88, Issue 4 , Pages 779-780 , October 2007

Article Tools